REFERENCES

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73.

2. Miyahara K, Nouso K, Yamamoto K. Image of the month. Hepatocellular carcinoma mimicking bile duct stone. Clin Gastroenterol Hepatol 2010;8:e17.

3. Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, et al. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer 2016;5:190-7.

4. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107.

5. Miyake Y, Iwasaki Y, Yamamoto K. Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. Int J Cancer 2010;127:989-96.

6. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-77.

7. Tateishi R, Okanoue T, Fujiwara N, Okita K, Kiyosawa K, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol 2015;50:350-60.

8. Archambeaud I, Auble H, Nahon P, Planche L, Fallot G, et al. Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis: the importance of prior obesity. Liver Int 2015;35:1872-6.

9. Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 2015; doi: 10.1111/hepr.12464.

10. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301-14.

11. International Diabetes Federation. IDF Diabetes Atlas - 8th edition. Available from: http://www.diabetesatlas.org. [Last accessed on 4 Dec 2018].

12. Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, et al. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. Eur J Cancer Prev 2009;18:26-32.

13. Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst 2012;104:1599-611.

14. Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, et al. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013;58:1253-62.

15. Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res 2015;45:152-61.

16. Takeuchi Y, Ikeda F, Osawa T, Araki Y, Takaguchi K, et al. Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. World J Hepatol 2015;7:2220-8.

17. Ricco G, Cavallone D, Cosma C, Caviglia GP, Oliveri F, et al. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers. Cancer Biomark 2018;21:603-612.

18. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.

19. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008;2:17-30.